NEUREN PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.65 AUD | -1.06% |
|
-1.43% | -25.31% |
| Apr. 24 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
| Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
| Sales 2024 * | 154M 101M | Sales 2025 * | 174M 114M | Capitalization | 2.41B 1.57B |
|---|---|---|---|---|---|
| Net income 2024 * | 92M 60.16M | Net income 2025 * | 96M 62.78M | EV / Sales 2024 * | 14.1 x |
| Net cash position 2024 * | 236M 154M | Net cash position 2025 * | 344M 225M | EV / Sales 2025 * | 11.9 x |
| P/E ratio 2024 * |
25.9
x | P/E ratio 2025 * |
25.2
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.96% |
More Fundamentals
* Assessed data
More news
Latest transcript on Neuren Pharmaceuticals Limited
More press releases
| 1 day | -1.06% | ||
| 1 week | -1.43% | ||
| Current month | -12.11% | ||
| 1 month | -7.86% | ||
| 3 months | -19.47% | ||
| 6 months | +83.20% | ||
| Current year | -25.31% |
1 week
18.36
19.86
1 month
18.3621.75
Current year
18.1625.30
1 year
10.0225.95
3 years
1.2025.95
5 years
0.9725.95
10 years
0.8225.95
| Managers | Title | Age | Since |
|---|---|---|---|
Jon Pilcher
CEO | Chief Executive Officer | 58 | 13-08-18 |
Lauren Frazer
DFI | Director of Finance/CFO | - | 20-07-31 |
Liza Squires
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 02-03-04 | |
Dianne Angus
BRD | Director/Board Member | 63 | 18-07-04 |
Jenny Lee Harry
BRD | Director/Board Member | - | 18-07-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +2.22% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 18.65 | -1.06% | 566 651 |
| 24-04-24 | 18.85 | -2.33% | 266,295 |
| 24-04-23 | 19.3 | +0.10% | 149,881 |
| 24-04-22 | 19.28 | +1.90% | 234,347 |
| 24-04-19 | 18.92 | -3.81% | 449,254 |
Delayed Quote Australian S.E., April 26, 2024 at 02:10 am EDT
More quotes
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Companyâs product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
18.85
AUD
Average target price
26.74
AUD
Spread / Average Target
+41.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.31% | 1.57B | |
| +24.91% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.51% | 233B | |
| +5.63% | 201B | |
| -10.14% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- NEU Stock
